Eisai

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Seed Therapeutics is a biotechnology company focused on developing targeted protein degradation therapeutics by harnessing and engineering molecules, including molecular glues, to attack protein targets implicated in cancer and neurodegenerative diseases. The company concentrates on research and development to create novel drug candidates for previously undruggable diseases.

RecoMed is South Africa's leading online healthcare booking platform. It connects patients with healthcare providers via a mobile-friendly portal, facilitating real-time appointments without phone calls or paperwork. The company offers white-label solutions to prominent clients like Discovery and Medicross.

Founded in 2007 by scientists from Washington University School of Medicine and LifeTech Research, C2N Diagnostics specializes in protein diagnostic testing services for neurological disorders. Utilizing mass spectrometry-based analysis, the company aims to provide accurate and sensitive diagnostics for conditions like Alzheimer's disease.

Hyku is a biotechnology company specializing in the development of precise covalent targeting of disease-causing proteins. Its platform identifies molecules that covalently bind non-cysteine amino acids, enabling the creation of innovative medicines designed to address challenges such as selectivity, druggability, and resistance across various diseases.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

Lifenet Insurance Company is a life insurance provider based in Tokyo, Japan, established in 2006. The company specializes in underwriting a variety of insurance products, including term death, whole life, medical, cancer, and disability insurance. Lifenet also offers health counseling services, catering to the diverse needs of its clientele. Notably, the company sells its products directly to consumers through the Internet, enhancing accessibility and customer engagement.

Founded in 2021 and based in South San Francisco, California, Tacit Therapeutics develops RNA-targeted treatments aimed at repairing mutated genes. The company innovates by repurposing existing human cell components to create broadly applicable, non-immunogenic gene modification methods.

Arteryex is a company focused on the development of systems and applications within the medical and healthcare sectors. It specializes in the commissioned development of tailored solutions and operates its own applications, including Pashatto Karte and the LEAF app, which supports health management for employees. Additionally, Arteryex has created an enterprise data management platform designed to optimize health management and medical care. This platform utilizes advanced technologies such as blockchain and artificial intelligence to enhance the retrieval and sharing of medical documents. By maximizing data utilization, Arteryex provides access to personal health record-related services for patients, healthcare professionals, and the broader community.

Ractigen Therapeutics is an early-stage pharmaceutical company dedicated to developing first-in-class therapies that selectively restore the expression of therapeutic genes silenced in diseased cells. Founded in 2016 by pioneers in the RNA activation field, the company leverages a groundbreaking discovery from the University of California San Francisco, known as RNA activation (RNAa). Ractigen's innovative approach aims to address diseases stemming from inadequate gene expression, with a focus on central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. The company is building a promising pipeline of candidate medicines to meet significant unmet medical needs.

Prism BioLab is focused on drug discovery and development, utilizing its proprietary PepMetics Technology to create therapeutic agents. The company specializes in treatments for non-oncology indications, particularly targeting conditions such as pulmonary fibrosis and other incurable diseases. By leveraging its innovative platform, Prism BioLab aims to provide effective solutions for these challenging health issues.

Neuroglee Health is a digital therapeutic platform focused on addressing the needs of patients in the early stages of neurodegenerative diseases. The company develops innovative therapeutic devices that offer treatment and monitoring tools aimed at preserving cognitive function and promoting patient independence. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee Health engages users on an individual basis, enabling them to take an active role in their treatment. The platform also provides consistent insights into the efficacy of therapies, which can facilitate accelerated drug development. Through its comprehensive approach, Neuroglee Health aims to empower patients and improve their quality of life while navigating the challenges posed by neurodegenerative conditions.

Sola Biosciences is a biotechnology company focused on developing transformative gene therapies for conformational diseases like Amyotrophic Lateral Sclerosis (ALS) and Huntington's disease (HD). The company employs its proprietary chaperone platform technology to selectively reduce abnormal proteins that cause toxic clumps in neurons, aiming to provide permanent treatment solutions. Additionally, Sola Biosciences has developed a modular bioreactor called 'Sola', enabling users to grow cells efficiently.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Voluntis, established in 2001, specializes in developing digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. The company offers products such as Insulia, Diabeo, Oleena, and AstraZeneca, which provide automated insulin dose recommendations, patient-specific dosage suggestions, and management of side effects like hypertension and diarrhea. Voluntis collaborates with pharmaceutical companies like Bristol-Myers Squibb to co-develop digital therapeutics for oncology. With a patient-centric approach, Voluntis aims to enhance medical practices and improve healthcare system efficiency through secure, collaborative, and innovative digital health solutions.

Allm develops digital platforms that leverage Information and Communication Technology (ICT) to improve healthcare accessibility and efficiency worldwide. Its solutions include medical communications platforms for professionals and patients, supporting over 18 countries across the Americas, Europe, Asia, and Africa.

Neuroglee Health is a digital therapeutic platform focused on addressing the needs of patients in the early stages of neurodegenerative diseases. The company develops innovative therapeutic devices that offer treatment and monitoring tools aimed at preserving cognitive function and promoting patient independence. By utilizing cognitive and neurobehavioral mechanisms, Neuroglee Health engages users on an individual basis, enabling them to take an active role in their treatment. The platform also provides consistent insights into the efficacy of therapies, which can facilitate accelerated drug development. Through its comprehensive approach, Neuroglee Health aims to empower patients and improve their quality of life while navigating the challenges posed by neurodegenerative conditions.

Unlearn.AI, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing innovative software tools for clinical research. Established in 2017, Unlearn.AI focuses on enhancing clinical trials through its unique digital twin technology, known as TwinRCT. This approach utilizes machine learning to create prognostic digital twins for individual patients, allowing for more accurate estimations of treatment effects while reducing the number of participants needed. The company also offers services for Clinical Trial Design, which helps determine inclusion criteria, endpoints, and study sizes, as well as Synthetic Control Arms that can minimize or eliminate the need for concurrent control groups. Additionally, Unlearn.AI provides Subgroup Analysis to identify and analyze specific patient subgroups within trial results. By integrating expertise from pharmaceuticals, medical technology, and machine learning, Unlearn.AI aims to transform clinical trials to improve outcomes for both patients and sponsors.

Darmiyan develops a SaaS platform, BrainSee, for early detection and monitoring of neurodegenerative diseases like Alzheimer's. Using standard MRI scans and cognitive tests, BrainSee generates detailed brain maps and scores indicating neurodegeneration, enabling timely diagnosis and intervention.

Caraway Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing innovative treatments for neurodegenerative diseases by modulating mitophagy and autophagy. The company aims to address the degradation of toxic cellular components, which is a key factor in various neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis. By leveraging an understanding of critical neural pathways, Caraway Therapeutics seeks to discover and develop novel small molecules that can restore cellular balance and improve lysosomal function. Founded in 2018 and initially known as Rheostat Therapeutics, Inc., the company rebranded in 2019 to reflect its commitment to finding effective therapies for patients affected by these debilitating diseases.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

Allm develops digital platforms that leverage Information and Communication Technology (ICT) to improve healthcare accessibility and efficiency worldwide. Its solutions include medical communications platforms for professionals and patients, supporting over 18 countries across the Americas, Europe, Asia, and Africa.

iPS PORTAL, Inc. is a Kyoto-based company established in 2014 that specializes in the development of instruments for analyzing and measuring cells, with a particular focus on induced pluripotent stem (iPS) cell technology. The company offers contract testing services for iPS cells, supporting researchers and healthcare companies in the practical application of this technology. Its services encompass research and development outsourcing, concept planning, and training programs in cell culture, all aimed at facilitating the advancement of drug discovery and regenerative medicine. By promoting the widespread use of iPS cell technology, iPS PORTAL plays a vital role in accelerating research and commercialization efforts within the healthcare sector.

AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.

SymBio Pharmaceuticals is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of pharmaceutical drugs. Its primary areas of focus are oncology and hematology. SymBio's portfolio includes Treakisym SyB L-0501 for treating various blood cancers, SyB L-1701 and SyB L-1702 for rapid infusion, Rigosertib SyB-C-0501 for solid tumors and systemic lupus erythematosus, SyB L-1101 for higher-risk myelodysplastic syndromes, SyB C-1101 for combination therapy with azacitidine, and SyB V-1901 for antiviral treatment. SymBio operates primarily in Asia.

MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care applications. The company markets its products through sales organizations in the United States, as well as alliances with other pharmaceutical or biotechnology companies internationally. MGI PHARMA, INC. was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, INC. in 1990. The company is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI PHARMA, INC. operates as a subsidiary of Eisai Corporation of North America.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.